<DOC>
	<DOCNO>NCT02553850</DOCNO>
	<brief_summary>This open non-randomized , single-arm , multicenter , observational study design evaluate correlation bone turnover marker response treatment patient breast cancer bone metastasis . In observational study , ibandronate ( Bondronat ) prescribe use accordance standard care . Data collect 12 month .</brief_summary>
	<brief_title>An Observational Study Patients With Breast Cancer Bone Metastases Receiving Ibandronate ( Bondronat )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>All criterion accordance Summary Product Characteristics Bondronat ( ibandronate ) Adult patient great ( &gt; ) 18 year age Histologically confirm breast cancer Confirmed bone metastasis ( bone scintigraphy , Xray , compute tomography magnetic resonance imaging ) Life expectancy &gt; 6 month No previous bisphosphonate therapy Patients sign write informed consent form study start All criterion accordance Summary Product Characteristics Bondronat ( ibandronate ) Hypersensitivity active substance excipients Bondronat ( ibandronate ) Hypersensitivity bisphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>